19:50 , Aug 3, 2017 |  BC Innovations  |  Strategy

FDA's phage philosophy

Against a backdrop of doubt about the regulators’ outlook for bacteriophage therapeutics, FDA is assuring drug developers the re-emerging modality is firmly on the table. The position should assuage at least some concerns in a...
21:44 , Feb 1, 2017 |  BC Week In Review  |  Clinical News

PAN-301-1: Ph I started

Panacea began an open-label, dose-escalation, U.S. Phase I trial to evaluate intradermal PAN-301-1 in about 18 patients. Panacea Pharmaceuticals Inc., Gaithersburg, Md.  Product: PAN-301-1  Business: Cancer  Molecular target: NA  Description: Cancer vaccine comprising neutralized bacteriophages presenting aspartate beta-hydroxylase (ASPH; HAAH)...
08:00 , Nov 19, 2007 |  BC Week In Review  |  Company News

Panacea Pharmaceuticals sales and marketing update

Panacea launched its CC Detect colon cancer diagnostic, which measures the level of human aspartyl (asparaginyl) beta- hydroxylase (HAAH) in blood. Panacea Pharmaceuticals Inc., Gaithersburg, Md.   Business: Diagnostic   ...
07:00 , Oct 22, 2007 |  BC Week In Review  |  Company News

Panacea Pharmaceuticals sales and marketing update

Panacea launched its BC Detect breast cancer diagnostic test, which measures levels of the cancer marker human aspartyl (asparaginyl) beta-hydroxylase (HAAH) in blood. Panacea Pharmaceuticals Inc., Gaithersburg, Md.   Business: Diagnostic   ...
08:00 , Jan 22, 2007 |  BC Week In Review  |  Clinical News

PC Detect: Pivotal trial started

Panacea started a U.S. pivotal trial in 600 subjects. Panacea Pharmaceuticals Inc., Gaithersburg, Md.   Product: PC Detect   Business: Diagnostic   Molecular target: NA   Description: Diagnostic screening test for prostate cancer which measures blood levels of...
07:00 , May 10, 2004 |  BC Week In Review  |  Company News

Panacea Pharmaceuticals, M.D. Anderson Cancer Center deal

Panacea and the center will collaborate to develop diagnostics and therapeutics for lung cancer based on the enzyme human aspartyl (asparaginyl) beta-hydroxylase ( HAAH). The center will provide archived serum and tissue samples and...
08:00 , Dec 22, 2003 |  BC Week In Review  |  Company News

Panacea Pharmaceuticals, SRL Inc. deal

Panacea granted SRL nonexclusive rights in Japan to develop cancer diagnostics based on Panacea's HAAH Oncology Program. The program targets the enzyme human aspartyl (asparaginyl) beta-hydroxylase (HAAH). Panacea received an upfront payment and...
08:00 , Dec 15, 2003 |  BC Week In Review  |  Company News

Panacea Pharmaceuticals, JSR Corp. deal

JSR will use its magnetic particle fabrication technology and surface chemistry to develop assays that measure human aspartyl (asparaginyl) beta-hydroxylase ( HAAH) for use in Panacea's HAAH oncology program. Panacea Pharmaceuticals Inc., Rockville, Md....
08:00 , Nov 24, 2003 |  BC Week In Review  |  Company News

Panacea Pharmaceuticals other research news

Using an ELISA assay, AAH was detected in the serum of 18 of 20 pancreatic cancer samples. Using an immunohistochemistry assay, all 9 pancreatic adenocarcinoma specimens tested were positive for AAH. A qRT-PCR assay showed...
08:00 , Nov 24, 2003 |  BC Week In Review  |  Company News

Panacea Pharmaceuticals other research news

In culture, antibodies against human AAH inhibited cellular proliferation and motility. Data were presented at the Molecular Targets and Cancer Therapeutics meeting in Boston. Panacea Pharmaceuticals Inc., Gaithersburg, Md.   Product: Monoclonal antibodies against human aspartyl/asparaginyl...